Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA
Authors:
Open Access
- 13 June 2017
- journal article
- research article
- Published by Taylor & Francis in Future Oncology
- Vol. 13 (19) , 1699-1710
Abstract
Aim: This retrospective study of patients in the USA with metastatic Merkel cell carcinoma (mMCC) aimed to assess patient responses to second-line and later (2L+) and first-line (1L) chemotherapy. Patients & methods: Out of 686 patients with MCC identified in The US Oncology Network, 20 and 67 patients with mMCC qualified for the 2L+ and 1L study, respectively; the primary analysis population was restricted to immunocompetent patients. Results: In the 2L+ primary analysis population, objective response rate (ORR) was 28.6%, median duration of response (DOR) was 1.7 months and median progression-free survival was 2.2 months. In the 1L primary analysis population, ORR was 29.4%, median DOR was 6.7 months and median progression-free survival was 4.6 months. Conclusion: The low ORR and brief DOR underscore the need for novel therapies.Keywords
Funding Information
- EMD Serono
This publication has 29 references indexed in Scilit:
- Systemic Immune Suppression Predicts Diminished Merkel Cell Carcinoma–Specific Survival Independent of StageJournal of Investigative Dermatology, 2013
- Tumor Infiltrating Immune Cells and Outcome of Merkel Cell Carcinoma: A Population-Based StudyClinical Cancer Research, 2012
- Merkel Cell Polyomavirus-Specific CD8+ and CD4+ T-cell Responses Identified in Merkel Cell Carcinomas and BloodClinical Cancer Research, 2011
- Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: Analysis of 5823 cases as the basis of the first consensus staging systemJournal of the American Academy of Dermatology, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU featuresJournal of the American Academy of Dermatology, 2008
- Clonal Integration of a Polyomavirus in Human Merkel Cell CarcinomaScience, 2008
- Merkel Cell Carcinoma: Prognosis and Treatment of Patients From a Single InstitutionJournal of Clinical Oncology, 2005
- Merkel cell carcinoma can be distinguished from metastatic small cell carcinoma using antibodies to cytokeratin 20 and thyroid transcription factor 1Journal of Clinical Pathology, 2001
- Chemotherapy of Metastatic Merkel Cell CarcinomaAmerican Journal of Clinical Oncology, 1991